Longitudinal development of communication in children with cerebral palsy between 24 and 53 months: Predicting speech outcomes.
Katherine C Hustad, Kristen M Allison, Ashley Sakash...
https://pubmed.ncbi.nlm.nih.gov/27792399/Actively Recruiting
Led by New York University · Updated on 2026-09-18
68
Participants Needed
2
Research Sites
30 weeks
Total Duration
Childhood apraxia of speech CAS is a challenging motor speech disorder that limits childrens ability to communicate effectively, often continuing into later life. Researchers are evaluating a new motor-based treatment called Dynamic Temporal and Tactile Cueing-Connect DTTC-Connect aimed at improving connected speech, where children with CAS usually face ongoing difficulties. This Phase II randomized controlled trial tests DTTC-Connects effectiveness in enhancing phrase accuracy, speech intelligibility, and speech motor control in children aged 3 years and 6 months to nearly 13 years. Participants receive DTTC-Connect treatment twice a week for eight weeks, with 45-minute sessions each time, totaling 16 sessions. The treatment uses a structured approach that gradually increases phrase complexity, starting from two-word phrases and progressing through levels of support to encourage independent speech production. The study includes two groups an Immediate Treatment Group beginning right after diagnostic evaluation, and a Delayed Treatment Group starting treatment after an 8-week wait to account for natural development. Throughout the study, children undergo assessments before, during, and after treatment, including detailed speech evaluations, acoustic and movement analyses of lip and jaw, and caregiver reports on communicative participation. The main outcome is phrase accuracy, measured at several points up to 16 weeks post-treatment. Secondary outcomes include speech intelligibility, speech motor variability, and communicative participation. These measures help researchers understand the lasting effects of DTTC-Connect and how prior treatment influences progress.
CONDITIONS
Motor-based Intervention for Childhood Apraxia of Speech: DTTC-Connect
M
Maria I Grigos, PhD
J
Julie Case, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
New York University
Lead Sponsor
Hofstra University
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Immediate DTTC‑Connect | Delayed DTTC‑Connect (Wait‑list) | Current motor‑based therapy (ReST or NDP3) |
|---|---|---|---|
| What it is | A structured motor‑based speech intervention (DTTC‑Connect) teaching phrase production through cueing hierarchies | The same DTTC‑Connect intervention is provided later following a delay period | Rapid Syllable Transition treatment (ReST) or Nuffield Dyspraxia Programme‑3 (NDP3) are widely used motor‑based therapies for CAS |
| Role in trial | Assigned to receive DTTC‑Connect therapy immediately | Assigned to a delayed‑treatment control group | Reflects current standard motor‑based options but not randomized in this study |
| Primary use | To improve speech accuracy and motor control in children with CAS | Same treatment provided after delay, serving as control for timing effects | Established motor‑based approaches to improve speech planning, prosody, and sequencing in CAS |
| How it is given | DTTC‑Connect delivered according to trial protocol (hierarchical cueing from simultaneous to elicited production) | Delivered later following waiting period matching immediate arm schedule | ReST uses non‑words and motor learning principles; NDP3 uses structured word targets with explicit feedback and cueing |
| Evidence status | Efficacy under investigation; evidence pending from this trial | Will serve to confirm whether observed gains are due to DTTC‑Connect rather than time | ReST and NDP3 both have RCT evidence showing improved speech accuracy with generalization and maintenance |
| Important risks | No safety risks reported; non‑invasive speech intervention | No safety risks reported; non‑invasive speech intervention | Non‑invasive behavioral therapies with no reported safety concerns |
| Important limitations | Effectiveness not yet established; trial pending completion | Delay control may raise ethical concerns if delayed intervention disadvantages some children | ReST and NDP3 require intensive practica (daily sessions) and trained providers, which may limit broad access |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 8 weeks
Participants receive DTTC-Connect treatment twice a week for 8 weeks, with 45-minute sessions focusing on improving connected speech through gradually more complex phrases.
Two sessions per week
Duration - 16 weeks post-treatment
Participants undergo speech evaluations and caregiver surveys at multiple time points up to 16 weeks after treatment to measure phrase accuracy, speech clarity, motor control, and communication participation.
Assessments at 1, 8, and 16 weeks post-treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Katherine C Hustad, Kristen M Allison, Ashley Sakash...
https://pubmed.ncbi.nlm.nih.gov/27792399/Maria I Grigos, Julie Case, Ying Lu...
https://pubmed.ncbi.nlm.nih.gov/38512002/Maria I Grigos, Julie Case, Ying Lu...
https://pubmed.ncbi.nlm.nih.gov/37379241/Julie Case, Emily W Wang, Maria I Grigos
https://pubmed.ncbi.nlm.nih.gov/37195724/Edwin Maas, Christina Gildersleeve-Neumann, Kathy Jakielski...
https://pubmed.ncbi.nlm.nih.gov/31425660/Elena Zaretsky, Shelley L Velleman, Kristina Curro
https://pubmed.ncbi.nlm.nih.gov/20380250/Edythe A Strand
https://pubmed.ncbi.nlm.nih.gov/31846588/Barbara A Lewis, Lisa A Freebairn, Amy J Hansen...
https://pubmed.ncbi.nlm.nih.gov/15191325/Maria I Grigos, Aviva Moss, Ying Lu
https://pubmed.ncbi.nlm.nih.gov/25951237/Edwin Maas, Kimberly A Farinella
https://pubmed.ncbi.nlm.nih.gov/22207698/New York University
Lead Sponsor
Hofstra University
Collaborating Sponsor